Using Electronic Health Record Tools to Improve Care for Patients Prescribed Opioids or with Opioid Use Disorder

  1. Opioid prescribing and care of patients with opioid use disorder can be challenging and heterogeneous.
  2. This session will teach the learner about the variety of tools available in the Mass General Brigham Electronic Health Record to improve safety in opioid prescribing, locate pertinent guidelines and reports, and meet state and federal requirements.
  3. As a result, clinicians will prescribe opioids more safely and deliver evidence-based care to patients with opioid use disorder

Target Audience

This activity in intended for physicians across the Mass General Brigham system.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Identify risk factors for development of opioid use disorder after an opioid prescription
  2. Implement best practices for prescribing opioids, including monitoring, limiting days’ supply and prescribing electronically
  3. Provide patients with instructions about safe use of injection drugs and naloxone to reverse opioid overdose
  4. Utilize reporting tools in the electronic health record to more safely care for patients prescribed opioids or with opioid use disorder

Additional Information

Provided by: 

Brigham & Women's Hospital & Mass General Brigham

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Course opens: 
09/16/2022
Course expires: 
09/16/2023
Cost:
$0.00

Evan Gale, MD - Course Director

Director of Clinical Education and Teaching
MGH Addiction Consult Team (ACT)
Massachusetts General Hospital

Scott Weiner, MD, MPH, FACEP, FAAEM

Scott Weiner, MD, MPH, FAAEM, FACEP, FASAM is an Associate Professor of Emergency Medicine at Harvard Medical School and the Chief of the Division of Health Policy and Public Health in the Department of Emergency Medicine at Brigham and Women’s Hospital.  Dr. Weiner completed his residency training at Beth Israel Deaconess Medical Center and MPH degree at Harvard School of Public Health.  He is board-certified in emergency medicine and addiction medicine. He is the Director of B-CORE: The Brigham Comprehensive Opioid Response and Education Program. He is also an active researcher, including working on multiple grant-funded projects from the NIH that focus on prevention and treatment of opioid use disorder.

In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Mass General Brigham designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Disclosure Summary of Relevant Financial Relationships

INELIGIBLE COMPANIES
Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers

For more information: https://accme.org/faq/what-accmes-definition-ineligible-company

MITIGATION STRATEGIES
Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.

The following planners have reported no relevant financial relationship with an ineligible company:

Evan Gale, MD

The following planners have reported relevant financial relationship with an ineligible company:

Scott Weiner, MD, MPH
Acute Pain Steering Committee: Vertex Pharmaceuticals, Inc.

The following speakers have reported relevant financial relationships an ineligible company:

Scott Weiner, MD, MPH
Acute Pain Steering Committee: Vertex Pharmaceuticals, Inc.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.